Hesham A. Abdullah, Senior Vice President of Global Head Oncology, Research and Development at GSK and Scientific Advisory Board (SAB) Member at Linden Lake Labs, Incorporation, shared on LinkedIn:
“Our ambition in oncology has always been to go wherever the best science takes us and today, that ambition takes a significant step forward with our major investment in the Cambridge Biomedical Campus.
Across our Global R/D organization, our teams are already doing ambitious work, turning scientific breakthroughs into medicines that change patients’ lives. This new site adds to that foundation, giving us a catalyst to further accelerate our research and help deliver the next wave of cancer medicines.
I’m particularly excited that our scientists in the UK will now be co-located with leading research institutions, hospitals and biotech companies, putting us directly in the UK’s ‘Golden Triangle‘ of life sciences, one more way we can pursue transformational oncology medicines with pace, precision and strategic collaboration, alongside the excellent work happening across our teams worldwide.
It’s a truly remarkable time to be leading in Oncology drug development, and I’m proud to be part of this new era of innovation at GSK, powered by the talent and dedication of our R/D community everywhere it stands.”
